Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

Asharq Al-Awsat

FDA limits use of Johnson & Johnson COVID vaccine over blood clot risks, agency says

The use of Johnson and Johnson’s COVID-19 vaccine, also known as Janssen, has been limited to “certain individuals” over rare blood clot risks, the U.S. Food and Drug Administration announced Thursday, May 5.

McClatchy Washington Bureau

Mum-of-two, 36, died from rare complications of Covid jab, inquest reveals

Mrs Wooldridge was found dead in her home by her brother in June last year, after she failed to collect her five-year-old son from school

Daily Mirror

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA restricts J&J's COVID-19 vaccine due to blood clot risk

U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots

The Independent UK

FDA Berates Pfizer CEO's Suggestion To Take More Paxlovid If COVID-19 Symptoms Rebound

The FDA berates Pfizer Inc (NYSE: PFE) CEO Albert Bourla's proposed solution in cases where virus levels rebound after the first course of treatment.

Benzinga

Commentary: COVID won’t become endemic until we have a vaccine for kids under 5

Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…

Los Angeles Times

COVID-19 dashboard: Catch up fast

The latest headlines that you need to know.

Axios

Read news from The Economist, FT, and more,
with one subscription

FDA contradicts Pfizer’s advice on 2nd course of COVID drug

There is “no evidence” that a second course of Pfizer Inc.’s Paxlovid will help COVID-19 patients whose symptoms return after an initial course of the antiviral, a U.S. Food and Drug Administration official said a day after Pfizer executives advocated the idea.

Tribune News Service

Pfizer opens global drug development centre on IIT-M Research Park campus

This is the company’s first such facility in Asia

The Hindu

4 Analysts Have This to Say About Pfizer

Within the last quarter, Pfizer (NYSE:PFE) has observed the following analyst ratings:

Benzinga

Will new vaccines be better at fighting coronavirus variants? 5 questions answered

The first three coronavirus vaccines earned Emergency Use Authorization more than a year ago. To date, no other vaccines have been put into use in the U.S – but that will soon change. More than 40 vaccines are undergoing clinical trials in the U.S., employing a number of different approaches…

The Conversation

Recombinant COVID variants: What is Omicron XE?

When large volumes of two viruses that are genetically linked circulate, there’s a risk of a new ‘hybrid’ virus forming.

Al Jazeera

Mid-Afternoon Market Update: Kymera Therapeutics Drops After Q1 Results; Belite Bio Shares Spike Higher

U.S. stocks traded slightly higher toward the end of trading on Tuesday.

Benzinga

Pfizer hopes to submit little-kid vaccine data by early June

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday.

Benzinga

Pfizer Stock Flies Higher Following Q1 Earnings Print: Here's What To Watch For Next

Pfizer, Inc (NYSE: PFE) shot up over 3% on Tuesday after printing its first-quarter earnings before the market open.

Benzinga

Mid-Morning Market Update: Markets Mixed; Dow Drops 50 Points

U.S. stocks traded mixed this morning, with the Dow Jones dropping around 50 points on Tuesday.

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer Posts Street Beating Q1 Earnings, Revises FY22 Profit Outlook

Pfizer Inc (NYSE:PFE) has reported a Q1 adjusted EPS of $1.62, up 72% Y/Y, well ahead of the consensus of $1.50. The company achieved revenues of $25.66 billion, up 77%, beating the Wall Street estimate of $23.95 billion. Its COVID-19 vaccine, Comirnaty, contributed $13.2 billion in direct sales and alliance revenues. Eliquis…

Benzinga

Pfizer: Q1 Earnings Insights

Pfizer (NYSE:PFE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:45 AM. Here's what investors need to know about the announcement. Earnings Pfizer beat estimated earnings by 8.0%, reporting an EPS of $1.62 versus an estimate of $1.5.

Birmingham Post

North East deals of the week: contracts, acquisitions and investments

Businesses involved in deals across the region include RSA Insurance, Roman Ltd, Tait Walker and ReViral

StockNews.com

3 High-Quality Stocks to Buy During This Market Selloff

The near-term market outlook remains cloudy. While the S&P 500 is about 3% above its late-February lows, the Nasdaq and Russell 2000 have already undercut these levels. Below are 3 such stocks that investors should consider buying during this market correction: Anthem (ANTM), Pfizer (PFE), and Builders FirstSource (BLDR).

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 16 strange trades.

Benzinga

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Daily Record

Lanarkshire senior nurse urges parents of young children to consider COVID-19 vaccine

The Pfizer vaccine was approved for youngsters in December 2021.

1 … 52 53 54 55

People

Jaimini DesaiJaimini Desai

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

323 stories

Pfizer Inc

312 stories

Centers for Disease Control and Prevention

304 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.